Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 566

1.

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ.

Lancet. 2015 Aug 1;386(9992):452-60. doi: 10.1016/S0140-6736(15)60158-1. Epub 2015 Jun 2.

PMID:
26047975
2.

[The alternative view on diagnostic of hyperlipoproteinemia, cholesterol lipoproteins of low density and effect of statins: a lecture].

Tupoleva TA, Tikhomirov DS, Grumbkova LO, Ignatova EN, Romanova TIu, Filatov FP, Garanzha TA.

Klin Lab Diagn. 2015 Jan;60(1):27-38. Russian.

PMID:
25874302
3.

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.

Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.

PMID:
25463129
4.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

5.

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ.

J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. Review.

6.

[Effect of simvastatin on atherosclerosis and central aortic pressure in ApoE gene knockout mice].

Liu M, Jin YH, Li TH, Shi LH, Zhu BQ.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):293-7. Chinese.

PMID:
24998652
7.

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.

Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB.

Vasc Health Risk Manag. 2014 May 7;10:279-90. doi: 10.2147/VHRM.S58694. eCollection 2014.

8.

Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.

Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, de Graaf J, Furberg CD, Sniderman A.

J Am Heart Assoc. 2014 Apr 14;3(2):e000759. doi: 10.1161/JAHA.113.000759.

9.

A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy.

Dimick SM, Sallee B, Asztalos BF, Pritchard PH, Frohlich J, Schaefer EJ.

J Clin Lipidol. 2014 Mar-Apr;8(2):223-30. doi: 10.1016/j.jacl.2013.11.005. Epub 2013 Dec 11.

PMID:
24636183
10.

Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia.

Yamasaki T, Iwashima Y, Jesmin S, Ohta Y, Kusunoki H, Hayashi S, Horio T, Kawano Y.

PLoS One. 2014 Feb 19;9(2):e89057. doi: 10.1371/journal.pone.0089057. eCollection 2014.

11.

Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.

Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N.

Scand J Clin Lab Invest. 2014 Jun;74(4):285-95. doi: 10.3109/00365513.2014.882015. Epub 2014 Feb 24.

PMID:
24564634
12.

Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome.

Bostan C, Yildiz A, Ozkan AA, Uzunhasan I, Kaya A, Yigit Z.

Angiology. 2015 Feb;66(2):122-7. doi: 10.1177/0003319714522107. Epub 2014 Feb 19.

PMID:
24554427
14.

Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice.

Jeon SM, Lee SA, Choi MS.

J Med Food. 2014 Mar;17(3):310-6. doi: 10.1089/jmf.2013.2885. Epub 2014 Jan 16.

15.

Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia.

Elshourbagy NA, Meyers HV, Abdel-Meguid SS.

Med Princ Pract. 2014;23(2):99-111. doi: 10.1159/000356856. Epub 2013 Dec 11. Review.

PMID:
24334831
16.

The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice.

Ying R, Yuan Y, Qin YF, Tian D, Feng L, Guo ZG, Sun YX, Li MX.

Lipids Health Dis. 2013 Dec 8;12:180. doi: 10.1186/1476-511X-12-180.

17.

ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.

de Nijs T, Sniderman A, de Graaf J.

Crit Rev Clin Lab Sci. 2013 Nov;50(6):163-71. doi: 10.3109/10408363.2013.847897. Review.

PMID:
24295059
18.

Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.

Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):427-32. doi: 10.1161/ATVBAHA.113.302019. Epub 2013 Nov 27.

19.

Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.

Lu T, Wen S, Cui Y, Ju SH, Li KC, Teng GJ.

Int J Cardiovasc Imaging. 2014 Jan;30(1):221-31. doi: 10.1007/s10554-013-0320-9. Epub 2013 Oct 30.

PMID:
24170262
20.

Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise.

Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, Saku K.

Circ J. 2013;77(11):2651-63. Epub 2013 Oct 10. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk